Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,656,456
  • Shares Outstanding, K 2,532,900
  • Annual Sales, $ 22,465 M
  • Annual Income, $ 3,001 M
  • 36-Month Beta 0.58
  • Price/Sales 4.39
  • Price/Cash Flow 11.66
  • Price/Book 6.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.36
  • Number of Estimates 3
  • High Estimate 0.46
  • Low Estimate 0.29
  • Prior Year 1.12
  • Growth Rate Est. (year over year) -67.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.88 +6.32%
on 10/12/18
40.16 -2.37%
on 10/03/18
+1.91 (+5.12%)
since 09/19/18
3-Month
36.88 +6.32%
on 10/12/18
40.16 -2.37%
on 10/03/18
+2.18 (+5.89%)
since 07/19/18
52-Week
31.99 +22.57%
on 12/06/17
40.16 -2.37%
on 10/03/18
+4.50 (+12.96%)
since 10/19/17

Most Recent Stories

More News
Agios Rides on Tibsovo Approval Amid Reliance on Celgene

Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.

AGIO : 66.88 (+0.09%)
CELG : 82.41 (-0.65%)
AZN : 39.21 (+0.67%)
MRK : 72.35 (+0.19%)
QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite

QIAGEN (QGEN) continues to expand test menu; latest European launch to boost portfolio and top line.

AZN : 39.21 (+0.67%)
DSRLF : 92.9300 (-14.14%)
QGEN : 35.91 (+1.30%)
PFE : 44.50 (+1.14%)
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs

Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well.

IRWD : 16.71 (-2.57%)
AZN : 39.21 (+0.67%)
AGN : 189.53 (+0.34%)
SGYP : 1.42 (-3.40%)
The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke

The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke

MA : 203.06 (-0.28%)
AZN : 39.21 (+0.67%)
LRCX : 145.20 (+0.08%)
PHG : 39.95 (-1.38%)
CRM : 140.49 (-1.65%)
Top Analyst Reports for AstraZeneca, Salesforce & Mastercard

Top Analyst Reports for AstraZeneca, Salesforce & Mastercard

MA : 203.06 (-0.28%)
E : 35.48 (+1.57%)
AZN : 39.21 (+0.67%)
LRCX : 145.20 (+0.08%)
PHG : 39.95 (-1.38%)
CRM : 140.49 (-1.65%)
Merck's Keytruda on a Roll in a Thriving Anti-PD-L1 Market

Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.

AZN : 39.21 (+0.67%)
MRK : 72.35 (+0.19%)
PFE : 44.50 (+1.14%)
BMY : 54.30 (-3.00%)
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status

AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.

CELG : 82.41 (-0.65%)
AZN : 39.21 (+0.67%)
MRK : 72.35 (+0.19%)
LLY : 111.92 (-1.23%)
3 Large-Cap Pharma Stocks Performing Better Than Industry

We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

AZN : 39.21 (+0.67%)
MRK : 72.35 (+0.19%)
LLY : 111.92 (-1.23%)
NVS : 87.19 (+1.10%)
SNY : 44.57 (+0.27%)
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.

BAYRY : 22.4850 (+0.33%)
AZN : 39.21 (+0.67%)
JNJ : 139.05 (-0.32%)
RHHBY : 30.5950 (+2.55%)
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.

CRSP : 36.04 (-3.12%)
AZN : 39.21 (+0.67%)
SNY : 44.57 (+0.27%)
MACK : 4.01 (-22.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade AZN with:

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

2nd Resistance Point 39.69
1st Resistance Point 39.45
Last Price 39.21
1st Support Level 39.03
2nd Support Level 38.84

See More

52-Week High 40.16
Last Price 39.21
Fibonacci 61.8% 37.04
Fibonacci 50% 36.08
Fibonacci 38.2% 35.11
52-Week Low 31.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar